Sort   by:  
 Page size 
UnknownPriority III: top 10 rapid review methodology research priorities identified using a James Lind Alliance Priority Setting Partnership.

Objectives

A rapid review is a form of evidence synthesis considered a resource-efficient alternative to the conventional systematic review. Despite a dramatic rise in the number of rapid reviews commissioned and conducted in response to the coronavirus disease 2019 pandemic, published evide...
S-EPMC9487890 | biostudies-literature
UnknownOxidative weathering decreases bioaccessibility of toxic metal(loid)s in PM10 emissions from sulfide mine tailings.
Environmental contamination from legacy mine-waste deposits is a persistent problem due to the long history of hard-rock mining. Sulfide ore deposits can contain elevated levels of toxic metal(loid)s that, when mobilized by weathering upon O2 and H2O infusion, can result in gro...
S-EPMC6191178 | biostudies-literature
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgG 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42019 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgM 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42020 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgG 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42163 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgM 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42175 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42145 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:200]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42150 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:200]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42179 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42176 | biostudies-arrayexpress
Sort   by:  
 Page size